Does a higher AA:EPA ratio shift eicosanoid signaling toward inflammation rather than resolution?

The relationship between arachidonic acid (AA) and eicosapentaenoic acid (EPA) is a fundamental determinant of the body's inflammatory landscape. The AA:EPA ratio serves as a critical biomarker for the competitive dynamics at the enzymatic level, directly influencing whether the body prioritizes the initiation or the resolution of inflammation.

Clinical and Mechanistic Evidence

Research consistently demonstrates that AA and EPA are direct competitors for the same enzymatic pathways, primarily involving cyclooxygenase (COX) and lipoxygenase (LOX).

• Enzymatic Competition: AA and EPA compete for the hydrophobic active sites of COX-1, COX-2, and 5-LOX. While AA is the high-affinity, preferred substrate for these enzymes, EPA acts as a competitive inhibitor. When the AA:EPA ratio is high, there is minimal EPA to displace AA, resulting in the rapid production of 2-series prostaglandins (e.g., PGE2) and 4-series leukotrienes (e.g., LTB4), which are potent drivers of pain, vasodilation, and leukocyte recruitment.
• Catalytic Efficiency: Kinetic studies show that enzymes metabolize AA significantly more efficiently than EPA. However, when EPA is abundant (a low AA:EPA ratio), it effectively occupies these active sites, even if it is processed more slowly. This reduces the total "pro-inflammatory load" by lowering the overall volume of AA-derived mediators produced.
• Signaling Shifts: A high AA:EPA ratio does more than just increase inflammatory signals; it actively impairs resolution. EPA serves as the direct precursor to E-series resolvins (such as RvE1). These specialized pro-resolving mediators (SPMs) are essential for "switching off" the inflammatory response, clearing cellular debris, and promoting tissue repair. High levels of AA relative to EPA essentially starve these resolution pathways of their required substrates.

Practical Implications

For a 44-year-old male, maintaining a balanced AA:EPA ratio is relevant for managing systemic inflammation and long-term cardiovascular and metabolic health.

• Resolution Failure: Chronic inflammation often results not from an overactive initiation phase, but from a failure of the resolution phase. A high ratio suggests the metabolic environment is biologically predisposed to sustained, rather than self-limiting, inflammation.
• Intervention: Lowering the ratio through omega-3 fatty acid intake has been shown to induce "eicosanoid class switching," where the metabolic output of COX and LOX enzymes shifts toward less inflammatory 3-series prostaglandins and protective resolvins.

Bottom line

A higher AA:EPA ratio reflects a biochemical environment where arachidonic acid dominates enzymatic active sites, leading to an overproduction of pro-inflammatory mediators and a deficit in the specialized pro-resolving mediators (SPMs) necessary to terminate the inflammatory response.